Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon [Yahoo! Finance]
Adagene Inc. - ADS, each representing 1.25 ordinary shares (ADAG)
Company Research
Source: Yahoo! Finance
colorectal cancer—well above a cited 2.5% ORR for nivolumab+ipilimumab—and Adagene says it will release an updated doublet dataset in the coming weeks to add patients and extend durability follow-up. Adagene positions ADG126 as a next-generation masked CTLA-4 antagonist using its SAFEbody mask and a different epitope to drive stronger ADCC/ADCP (company claims ~10x vs ipilimumab), enabling higher dosing with favorable tolerability and supporting combination strategies including a triplet with fruquintinib and collaborations with Roche and Sanofi. Interested in Adagene Inc. Sponsored ADR? Here are five stocks we like better. Adagene (NASDAQ:ADAG) outlined its clinical and strategic priorities at Leerink Partners' global healthcare conference, with Chief Strategy Officer Mickael Chane-Du focusing primarily on the company's lead program, ADG126, and its progress in metastatic microsatellite-stable colorectal cancer (MSS CRC) and other tumor types. ADG126 positioning and different
Show less
Read more
Impact Snapshot
Event Time:
ADAG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAG alerts
High impacting Adagene Inc. - ADS, each representing 1.25 ordinary shares news events
Weekly update
A roundup of the hottest topics
ADAG
News
- Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA [Yahoo! Finance]Yahoo! Finance
- Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CAGlobeNewswire
- Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk [Yahoo! Finance]Yahoo! Finance
- Adagene to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Adagene to Participate in Two Upcoming Investor ConferencesGlobeNewswire
ADAG
Sec Filings
- 3/18/26 - Form SCHEDULE
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- ADAG's page on the SEC website